IL-27: A Promising Drug Target and Biomarker (G246778)

Target Name: IL27

NCBI ID: G246778

IL27

IL-27: A Promising Drug Target and Biomarker

Interleukin 27 (IL-27), a cytokine that plays a crucial role in the regulation of immune and inflammatory responses, has recently been identified as a potential drug target and biomarker for various diseases, including cardiovascular diseases, neuroinflammatory disorders, and autoimmune diseases.

IL-27 is a cytokine that is produced by various immune cells, including T cells, B cells, and macrophages. It is a key mediator of the immune response and has been involved in the regulation of various physiological processes, including cell growth, differentiation, and inflammation.

One of the key functions of IL-27 is its role in the regulation of immune cell function. IL-27 has been shown to promote the growth and survival of immune cells, and it has been shown to play a key role in the regulation of T cell development and function.

In addition to its role in immune cell function, IL-27 has also been shown to have a variety of potential therapeutic applications. For example, IL-27 has been shown to have anti-inflammatory effects and to protect against neurodegeneration in various models, including models of multiple sclerosis and neurofibrillary tangles.

IL-27 has also been shown to have potential applications as a biomarker for various diseases. For example, studies have shown that IL-27 levels are elevated in the blood of individuals with heart failure, and that levels of IL-27 have been associated with increased risk of mortality in individuals with neurocancer.

In addition to its potential therapeutic and biomarker applications, IL-27 is also of interest as a potential drug target. Several studies have shown that IL-27 can interact with a variety of drug targets, including those involved in cell signaling, inflammation, and stress signaling.

One potential mechanism by which IL-27 may interact with drug targets is through its role as a signaling molecule. IL-27 has been shown to interact with a variety of cytokine signaling pathways, including those involved in cell growth, differentiation, and inflammation.

IL-27 has also been shown to interact with a variety of protein targets, including those involved in cell signaling, inflammation, and stress signaling. For example, studies have shown that IL-27 can interact with the protein FAK, which is involved in cell signaling and has been implicated in a variety of diseases, including cancer and neurodegeneration.

In addition to its potential role as a signaling molecule, IL-27 may also interact with other drug targets that are involved in its function as a cytokine. For example, IL-27 has been shown to interact with the protein CSF-1, which is involved in cell signaling and has been implicated in a variety of diseases, including cancer and autoimmune diseases.

Overall, IL-27 is a cytokine that has been shown to have a variety of potential therapeutic and biomarker applications. Its role as a signaling molecule and its potential interactions with drug targets make it an attractive target for further research and development. As research continues to advance, it is likely that IL-27 will become a key player in the development of new treatments for a variety of diseases.

Protein Name: Interleukin 27

Functions: Associates with EBI3 to form the IL-27 interleukin, a heterodimeric cytokine which functions in innate immunity. IL-27 has pro- and anti-inflammatory properties, that can regulate T-helper cell development, suppress T-cell proliferation, stimulate cytotoxic T-cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells. Among its target cells are CD4 T-helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells. It also strongly synergizes with IL-12 to trigger interferon-gamma/IFN-gamma production of naive CD4 T-cells, binds to the cytokine receptor WSX-1/TCCR which appears to be required but not sufficient for IL-27-mediated signal transduction. IL-27 potentiate the early phase of TH1 response and suppress TH2 and TH17 differentiation. It induces the differentiation of TH1 cells via two distinct pathways, p38 MAPK/TBX21- and ICAM1/ITGAL/ERK-dependent pathways. It also induces STAT1, STAT3, STAT4 and STAT5 phosphorylation and activates TBX21/T-Bet via STAT1 with resulting IL12RB2 up-regulation, an event crucial to TH1 cell commitment. It suppresses the expression of GATA3, the inhibitor TH1 cells development. In CD8 T-cells, it activates STATs as well as GZMB. IL-27 reveals to be a potent inhibitor of TH17 cell development and of IL-17 production. Indeed IL27 alone is also able to inhibit the production of IL17 by CD4 and CD8 T-cells. While IL-27 suppressed the development of pro-inflammatory Th17 cells via STAT1, it inhibits the development of anti-inflammatory inducible regulatory T-cells, iTreg, independently of STAT1. IL-27 has also an effect on cytokine production, it suppresses pro-inflammatory cytokine production such as IL2, IL4, IL5 and IL6 and activates suppressors of cytokine signaling such as SOCS1 and SOCS3. Apart from suppression of cytokine production, IL-27 also antagonizes the effects of some cytokines such as IL6 through direct effects on T-cells. Another important role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines such as IP-10/CXCL10 and MIG/CXCL9. In vein endothelial cells, it induces IRF1/interferon regulatory factor 1 and increase the expression of MHC class II transactivator/CIITA with resulting up-regulation of major histocompatibility complex class II. IL-27 also demonstrates antiviral activity with inhibitory properties on HIV-1 replication

The "IL27 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL27 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets